KEI on Moderna's Oct 8, 2020 Statement on Intellectual Property Matters during the COVID-19 Pandemic | Knowledge Ecology International

"Moderna’s statement on intellectual property matters during the COVID-19 pandemic is very good, and should be matched by every manufacturer of a therapeutic, vaccine or diagnostic test. We also encourage Moderna to engage with the WHO COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool. Every manufacturer of a vaccine, drug or diagnostic should follow suit and publish the patents relevant to the technology, waive or license rights in those patents, and  provide constructive transfer of manufacturing know-how and access to cell lines and data when necessary.

It is notable that Moderna has addressed both the  pandemic and the post pandemic period, stating “to eliminate any perceived IP barriers to vaccine development during the pandemic period, upon request we are also willing to license our intellectual property for COVID-19 vaccines to others for the post pandemic period.” ..."